Stocktoria
Silo Pharma, Inc. SILO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-01-05
Silo Pharma, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 38.6% | 91.9% | 91.9% | 91.9% | — |
| Operating margin | -5937.0% | -6526.4% | -5347.4% | -5031.3% | — |
| Net margin | -5863.5% | -6092.6% | -5132.6% | -5420.9% | — |
| Return on assets | -55.6% | -59.3% | -47.8% | -33.6% | 37.2% |
| Return on equity | -67.0% | -87.3% | -59.9% | -37.8% | 43.1% |
| Current ratio | 11.36 | 4.29 | 9.90 | 26.52 | 21.23 |
| Revenue growth | 0.0% | 0.0% | 0.0% | — | — |
Source: SEC EDGAR filings · CIK 0001514183 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.